LIMN (Liminatus Pharma) PB Ratio: (As of Jun. 26, 2026)


What is Liminatus Pharma PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), Liminatus Pharma's share price is $0.106. Liminatus Pharma's Book Value per Share for the quarter that ended in Mar. 2026 was $-0.00. Hence, Liminatus Pharma's PB Ratio of today is .

The historical rank and industry rank for Liminatus Pharma's PB Ratio or its related term are showing as below:

LIMN's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.8
* Ranked among companies with meaningful PB Ratio only.

During the past 3 years, the average Book Value Per Share Growth Rate was 4.40% per year.

During the past 4 years, the highest 3-Year average Book Value Per Share Growth Rate of Liminatus Pharma was 4.40% per year. The lowest was 4.40% per year. And the median was 4.40% per year.

Back to Basics: PB Ratio


Liminatus Pharma  (NAS:LIMN) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Liminatus Pharma PB Ratio Related Terms


Liminatus Pharma PB Ratio Historical Data

* Premium members only.

The historical data trend for Liminatus Pharma's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Liminatus Pharma PB Ratio Chart

Liminatus Pharma Annual Data
Trend Dec22 Dec23 Dec24 Dec25
PB Ratio
0.00 0.00 0.00 0.00

Liminatus Pharma Quarterly Data
Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LIMN vs XBIO, PCSA, SILO: PB Ratio Comparison

For the Biotechnology subindustry, Liminatus Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Liminatus Pharma PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Liminatus Pharma's PB Ratio distribution charts can be found below:

* The bar in red indicates where Liminatus Pharma's PB Ratio falls into.



Liminatus Pharma PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Liminatus Pharma's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2026)
=0.106/-0.003
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Liminatus Pharma Business Description

Address 12611 Hiddencreek Way, Unit C, Cerritos, CA, USA, 90703
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.